Q2 Earnings Estimate for RYTM Issued By Leerink Partnrs

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – Investment analysts at Leerink Partnrs reduced their Q2 2025 earnings per share (EPS) estimates for Rhythm Pharmaceuticals in a report released on Sunday, July 13th. Leerink Partnrs analyst F. Khurshid now anticipates that the company will earn ($0.88) per share for the quarter, down from their previous forecast of ($0.86). Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($4.32) per share. Leerink Partnrs also issued estimates for Rhythm Pharmaceuticals’ Q3 2025 earnings at ($0.98) EPS, Q4 2025 earnings at ($1.06) EPS, FY2025 earnings at ($3.73) EPS, Q1 2026 earnings at ($0.97) EPS, Q2 2026 earnings at ($0.92) EPS, Q3 2026 earnings at ($0.80) EPS and FY2026 earnings at ($3.30) EPS.

Several other research firms have also recently weighed in on RYTM. Wells Fargo & Company raised their target price on shares of Rhythm Pharmaceuticals from $91.00 to $129.00 and gave the company an “overweight” rating in a research note on Thursday, July 10th. Guggenheim reissued a “buy” rating on shares of Rhythm Pharmaceuticals in a research report on Thursday, July 10th. JMP Securities restated a “market outperform” rating and set a $84.00 price objective on shares of Rhythm Pharmaceuticals in a research note on Thursday, June 26th. Oppenheimer set a $110.00 target price on shares of Rhythm Pharmaceuticals and gave the company an “outperform” rating in a report on Thursday, July 10th. Finally, Canaccord Genuity Group lifted their price target on Rhythm Pharmaceuticals from $81.00 to $92.00 and gave the stock a “buy” rating in a report on Tuesday, April 8th. Fourteen research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $91.00.

Rhythm Pharmaceuticals Stock Up 2.3%

RYTM stock opened at $91.44 on Wednesday. The company has a market cap of $5.82 billion, a price-to-earnings ratio of -32.54 and a beta of 2.26. Rhythm Pharmaceuticals has a twelve month low of $40.61 and a twelve month high of $94.80. The business has a 50 day moving average price of $65.90 and a two-hundred day moving average price of $59.97.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last released its earnings results on Wednesday, May 7th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.12). Rhythm Pharmaceuticals had a negative net margin of 123.26% and a negative return on equity of 739.62%. The business had revenue of $37.72 million during the quarter, compared to the consensus estimate of $40.43 million. During the same period last year, the business posted ($2.35) EPS. The firm’s revenue for the quarter was up 25.9% on a year-over-year basis.

Insider Buying and Selling at Rhythm Pharmaceuticals

In related news, insider Joseph Shulman sold 7,969 shares of the firm’s stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $77.78, for a total value of $619,828.82. Following the sale, the insider directly owned 8,509 shares of the company’s stock, valued at $661,830.02. This trade represents a 48.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Pamela J. Cramer sold 15,572 shares of Rhythm Pharmaceuticals stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $77.13, for a total value of $1,201,068.36. Following the completion of the transaction, the insider owned 19,209 shares in the company, valued at approximately $1,481,590.17. This represents a 44.77% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 93,673 shares of company stock valued at $7,118,510 over the last three months. 6.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of RYTM. Toth Financial Advisory Corp bought a new position in Rhythm Pharmaceuticals in the 2nd quarter valued at approximately $632,000. Assenagon Asset Management S.A. increased its position in Rhythm Pharmaceuticals by 972.4% in the 2nd quarter. Assenagon Asset Management S.A. now owns 237,998 shares of the company’s stock valued at $15,039,000 after acquiring an additional 215,806 shares during the period. Harbor Capital Advisors Inc. raised its stake in shares of Rhythm Pharmaceuticals by 12.0% during the second quarter. Harbor Capital Advisors Inc. now owns 86,546 shares of the company’s stock valued at $5,469,000 after acquiring an additional 9,249 shares during the last quarter. E. Ohman J or Asset Management AB bought a new position in shares of Rhythm Pharmaceuticals during the second quarter valued at $519,000. Finally, Rhumbline Advisers lifted its holdings in shares of Rhythm Pharmaceuticals by 3.6% during the first quarter. Rhumbline Advisers now owns 85,719 shares of the company’s stock worth $4,541,000 after purchasing an additional 2,988 shares during the period.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.